# Doctolib
Doctolib is a French health technology company, founded in April 2013 by Stanislas Niox-Chateau, that sells subscription practice-management software to health professionals and runs a patient-facing booking platform and telehealth service across France, Germany, Italy and, since 2026, the United Kingdom. Contrary to any report of a shutdown or acquisition, the company is operating as an independent private company: an April 2026 secondary share sale valued it at €3.6 billion, and its June 2026 legal record shows an active French société par actions simplifiée with Niox-Chateau still as its publication director.[1](https://www.bloomberg.com/news/articles/2026-04-02/startup-doctolib-s-valuation-slides-38-in-secondary-share-sale) • [2](https://media.doctolib.com/image/upload/v1784554001/legal/legal/Update%20June%202026%20FR/B2C-Legal-Mentions-FR-June_26.pdf)
| Fact | Detail |
| --- | --- |
| Founded | April 2013[3](https://media.doctolib.com/image/upload/mkg/file/impact_report_en_digital.pdf) |
| Founder and CEO | Stanislas Niox-Chateau[2](https://media.doctolib.com/image/upload/v1784554001/legal/legal/Update%20June%202026%20FR/B2C-Legal-Mentions-FR-June_26.pdf) |
| Headquarters | 54 quai Charles Pasqua, 92300 Levallois-Perret, France[2](https://media.doctolib.com/image/upload/v1784554001/legal/legal/Update%20June%202026%20FR/B2C-Legal-Mentions-FR-June_26.pdf) |
| Sector | Healthtech: practice-management software, appointment booking, telehealth[3](https://media.doctolib.com/image/upload/mkg/file/impact_report_en_digital.pdf) |
| Largest funding round | €500 million (equity and debt) at €5.8 billion valuation, March 2022[4](https://www.lefigaro.fr/conjoncture/sante-doctolib-leve-500-millions-d-euros-pour-doubler-ses-effectifs-en-cinq-ans-20220315) |
| Main investors | Bpifrance and Eurazeo led the 2022 round[4](https://www.lefigaro.fr/conjoncture/sante-doctolib-leve-500-millions-d-euros-pour-doubler-ses-effectifs-en-cinq-ans-20220315) |
| Scale (self-reported, 2024) | 50 million patients in France; 15 million online appointments booked per month[3](https://media.doctolib.com/image/upload/mkg/file/impact_report_en_digital.pdf) |
| Status (2026) | Operating private company; April 2026 secondary sale at €3.6 billion valuation[1](https://www.bloomberg.com/news/articles/2026-04-02/startup-doctolib-s-valuation-slides-38-in-secondary-share-sale) |
## Founding and history
The company's own timeline records its creation in April 2013.[3](https://media.doctolib.com/image/upload/mkg/file/impact_report_en_digital.pdf) Stanislas Niox-Chateau is named as founder and chief executive in the company's legal record, where he appears as publication director.[2](https://media.doctolib.com/image/upload/v1784554001/legal/legal/Update%20June%202026%20FR/B2C-Legal-Mentions-FR-June_26.pdf)
The product expanded from booking software into a broader suite. Telehealth launched in 2019; in March 2021 the company released "Doctolib Médecin", which it describes as a next-generation medical software for practitioners; and in April 2023 it launched Doctolib Kiné, a version for physiotherapists. In February 2023 it merged with Siilo, a secure medical messaging provider, and in early 2023 it adopted purpose-driven company status with a Mission Committee.[3](https://media.doctolib.com/image/upload/mkg/file/impact_report_en_digital.pdf)
## Products and business model
Doctolib is all three of the things readers often ask about, in one stack: practice-management software for clinicians, a booking platform where patients find and schedule appointments, and a telehealth service. According to the company's own impact report, the business model relies on a commitment-free subscription paid by health professionals and institutions to access the software suite; patients use the booking service without a described charge.[3](https://media.doctolib.com/image/upload/mkg/file/impact_report_en_digital.pdf) The Siilo secure messaging service the company merged with had 240,000 professional users exchanging more than 4 million documents per month, by the company's figure.[3](https://media.doctolib.com/image/upload/mkg/file/impact_report_en_digital.pdf) The company also claims that general practitioners and pediatricians using its software save 4.5 hours of medical time per week; this is the company's own estimate, not an independent measurement.[3](https://media.doctolib.com/image/upload/mkg/file/impact_report_en_digital.pdf)
## Funding and valuation, by the numbers
- **March 2022:** €500 million in equity and debt at a €5.8 billion valuation, led mainly by the historical investors [Bpifrance](https://www.edgepedia.org/bpifrance) and Eurazeo, making Doctolib France's most valuable startup at the time. The company said it would grow headcount from 2,500 to 3,500 across France, Germany, and Italy.[4](https://www.lefigaro.fr/conjoncture/sante-doctolib-leve-500-millions-d-euros-pour-doubler-ses-effectifs-en-cinq-ans-20220315)
- **April 2026:** employees and early investors sold about €300 million ($345 million) of shares in a secondary sale, per the company, at a €3.6 billion valuation, roughly a 38% discount to the 2022 mark.[1](https://www.bloomberg.com/news/articles/2026-04-02/startup-doctolib-s-valuation-slides-38-in-secondary-share-sale)
The 2026 discount tracks a broader repricing of European healthtech valuations after 2022 rather than a distress event: the company kept operating and expanding through the period, and no source documents layoffs or a profitability announcement. No absolute revenue figure is available in the retained sources; only Germany's share of annual recurring revenue, about 20%, is reported.[5](https://www.healthcare.digital/single-post/doctolib-s-40-secondary-market-devaluation-primary-drivers-of-european-healthtech-market-recalibra)
## Traction and scale
At the 2022 raise, Doctolib reported 60 million European users of its booking platform.[4](https://www.lefigaro.fr/conjoncture/sante-doctolib-leve-500-millions-d-euros-pour-doubler-ses-effectifs-en-cinq-ans-20220315) Its 2024 impact report claims 50 million patients in France and 15 million online appointments booked per month, half of them outside office hours.[3](https://media.doctolib.com/image/upload/mkg/file/impact_report_en_digital.pdf) Germany is the growth engine among its markets, contributing about 20% of total ARR and 28% of new revenues in the first quarter of 2025.[5](https://www.healthcare.digital/single-post/doctolib-s-40-secondary-market-devaluation-primary-drivers-of-european-healthtech-market-recalibra) Later reporting puts the company at approximately 80 to 90 million patient accounts across Europe and more than 400,000 health professionals on paid subscriptions.[6](https://techshali.com/doctolib/) Retained sources do not make head-to-head comparisons with Zocdoc, Kry, Jameda, or Qare, but the competition authority's market-share findings (below) show how dominant Doctolib became in France specifically.
## COVID-19 and the vaccine-booking moment
Doctolib became an official partner of the French government for the COVID-19 vaccination campaign, and its platform handled 81 million vaccination appointments in 2021, according to CEO Stanislas Niox-Chateau.[3](https://media.doctolib.com/image/upload/mkg/file/impact_report_en_digital.pdf) • [4](https://www.lefigaro.fr/conjoncture/sante-doctolib-leve-500-millions-d-euros-pour-doubler-ses-effectifs-en-cinq-ans-20220315) The same period transformed the demand side of its business: telemedicine in France jumped from 1% of total medical visits to 17% within months, a shift that directly fed Doctolib's téléconsultation product.[5](https://www.healthcare.digital/single-post/doctolib-s-40-secondary-market-devaluation-primary-drivers-of-european-healthtech-market-recalibra)
## Controversies and disputes
**Competition fine.** On November 6, 2025, the French Competition Authority (Autorité de la concurrence) fined Doctolib €4,665,000 for abuse of a dominant position in the markets for online medical appointment booking and remote consultation technology.[7](https://www.clearygottlieb.com/news-and-insights/publication-listing/below-threshold-merger-found-abusive-and-sanctioned-for-the-first-time-by-the-fca) The authority found Doctolib's client-volume market share rose from 54% in 2017 to 66% in 2018 and stabilized around 80% from 2019, with value-based shares reaching 99% in 2019.[7](https://www.clearygottlieb.com/news-and-insights/publication-listing/below-threshold-merger-found-abusive-and-sanctioned-for-the-first-time-by-the-fca) Most of the fine, €4,615,000, covered foreclosure practices: until September 2023, subscription contracts contained an exclusivity clause and an "anti-allocation" clause discouraging use of competing booking solutions, which the authority found were retained despite Doctolib's own legal department warning the CEO of their illegality.[8](https://webiis08.mondaq.com/france/antitrust-eu-competition/1708014/french-competition-authorityfor-the-first-timesanctions-below-threshold-deal-under-abuse-of-dominance-provisions) The remaining €50,000 sanctioned the 2018 acquisition of competitor MonDocteur as a non-notifiable "killer acquisition", the first time the French authority used this route under the Towercast ruling; the authority found the deal brought Doctolib 10,000 health professionals and allowed price increases "higher than initially planned" without customer losses.[7](https://www.clearygottlieb.com/news-and-insights/publication-listing/below-threshold-merger-found-abusive-and-sanctioned-for-the-first-time-by-the-fca) • [8](https://webiis08.mondaq.com/france/antitrust-eu-competition/1708014/french-competition-authorityfor-the-first-timesanctions-below-threshold-deal-under-abuse-of-dominance-provisions) The authority also found Doctolib tied its Téléconsultation product to its booking service, with teleconsultation accessible only one month after downloading the Doctolib Patient app. The investigation began after a complaint by competitor Cegedim Santé and included unannounced inspections in 2021; Doctolib announced it would appeal.[7](https://www.clearygottlieb.com/news-and-insights/publication-listing/below-threshold-merger-found-abusive-and-sanctioned-for-the-first-time-by-the-fca) • [8](https://webiis08.mondaq.com/france/antitrust-eu-competition/1708014/french-competition-authorityfor-the-first-timesanctions-below-threshold-deal-under-abuse-of-dominance-provisions)
**Data protection.** In 2022, data-protection advocates questioned Doctolib's processing of patient health metadata, and the Berlin data protection authority has received repeated complaints about its German operations; in 2023, an internal error led to the accidental deletion of thousands of consultation records. Both items come from a weaker secondary source, so the details carry more uncertainty than the competition findings above.[6](https://techshali.com/doctolib/)
## Recent developments, and status in 2026
Doctolib has kept expanding rather than retrenching. After the February 2023 Siilo merger and the April 2023 launch of Doctolib Kiné, it acquired London-based Medicus, a developer of clinical software for the NHS, in May 2026 and announced a £100 million UK expansion, making the United Kingdom its fifth market.[9](https://sifted.eu/articles/doctolib-acquires-medicus-uk-expansion)
On status: the company remains independent and operating. Its June 2026 legal mentions show a French société par actions simplifiée with share capital of €202,660.15, registered at the RCS of Nanterre under number 794 598 813, headquartered at 54 quai Charles Pasqua in Levallois-Perret, with Stanislas Niox-Chateau as publication director.[2](https://media.doctolib.com/image/upload/v1784554001/legal/legal/Update%20June%202026%20FR/B2C-Legal-Mentions-FR-June_26.pdf) Together with the April 2026 secondary sale at €3.6 billion, this contradicts any report that Doctolib shut down or was acquired.[1](https://www.bloomberg.com/news/articles/2026-04-02/startup-doctolib-s-valuation-slides-38-in-secondary-share-sale) Questions the retained sources do not settle include the early co-founding story, absolute revenue, and any layoffs or profitability milestones after 2022.
## References
1. [French Startup Doctolib Sees Valuation Fall in €300 Million Share Sale (Bloomberg, April 2026)](https://www.bloomberg.com/news/articles/2026-04-02/startup-doctolib-s-valuation-slides-38-in-secondary-share-sale)
2. [Doctolib Legal Mentions, June 2026 (Doctolib)](https://media.doctolib.com/image/upload/v1784554001/legal/legal/Update%20June%202026%20FR/B2C-Legal-Mentions-FR-June_26.pdf)
3. [Doctolib Impact Report 2024 (Doctolib)](https://media.doctolib.com/image/upload/mkg/file/impact_report_en_digital.pdf)
4. [Doctolib lève 500 millions et devient la plus grosse licorne française (Le Figaro, March 2022)](https://www.lefigaro.fr/conjoncture/sante-doctolib-leve-500-millions-d-euros-pour-doubler-ses-effectifs-en-cinq-ans-20220315)
5. [Doctolib's Secondary Market Devaluation (healthcare.digital)](https://www.healthcare.digital/single-post/doctolib-s-40-secondary-market-devaluation-primary-drivers-of-european-healthtech-market-recalibra)
6. [Doctolib: A French Startup Became Europe's Healthcare Platform (TechShali)](https://techshali.com/doctolib/)
7. [Below-Threshold Merger Found Abusive and Sanctioned for the First Time by the FCA (Cleary Gottlieb)](https://www.clearygottlieb.com/news-and-insights/publication-listing/below-threshold-merger-found-abusive-and-sanctioned-for-the-first-time-by-the-fca)
8. [French Competition Authority sanctions below-threshold deal under abuse of dominance provisions (Mondaq)](https://webiis08.mondaq.com/france/antitrust-eu-competition/1708014/french-competition-authorityfor-the-first-timesanctions-below-threshold-deal-under-abuse-of-dominance-provisions)
9. [Health unicorn Doctolib plots £100m UK expansion, acquires London-based Medicus (Sifted, May 2026)](https://sifted.eu/articles/doctolib-acquires-medicus-uk-expansion)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Digital health and health IT companies › Health IT and services software*
*Initially written Sep 17, 2026 · Edited: Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license